503953849 08/10/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

SUBMISSION TYPE: CORRECTIVE ASSIGNMENT **NATURE OF CONVEYANCE:** Corrective Assignment to correct the GANYMED PHARMACEUTICALS AG FREILIGRATHSTRASSE 12 MAINZ, GERMANY 55131 previously recorded on Reel 030032 Frame 0621. Assignor(s) hereby confirms the GANYMED PHARMACEUTICALS AG AN DER GOLDGRUBE 12 MAINZ, **GERMANY 55131.**

CONVEYING PARTY DATA

Name	Execution Date
UGUR SAHIN	01/17/2013
OZLEM TURECI	01/21/2013
MICHAEL KOSLOWSKI	01/19/2013
KORDEN WALTER	01/17/2013
MARIA KREUZBERG	01/17/2013
SYLVIA LUXEN	01/17/2013

RECEIVING PARTY DATA

Name:	GANYMED PHARMACEUTICALS AG
Street Address:	AN DER GOLDGRUBE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
Name:	JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Name: Street Address:	JOHANNES GUTENBERG-UNIVERSITAT MAINZ SAARSTRASSE 21
Street Address:	SAARSTRASSE 21

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	13808423	

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: mhmpto@mcandrews-ip.com

Correspondent Name: MCANDREWS HELD & MALLOY, LTD.

Address Line 1: 500 W MADISON ST

PATENT

EPAS ID: PAT4000505

REEL: 039641 FRAME: 0343 503953849

Address Line 2: 34TH	I FLOOR	
Address Line 4: CHIC	AGO, ILLINOIS 60661	
ATTORNEY DOCKET NUMBER:	26413US01	
NAME OF SUBMITTER:	GEORGE T. WU	
SIGNATURE:	/George T. Wu/	
DATE SIGNED:	08/10/2016	
Total Attachments: 12		
source=26413US01_Original_Assignme	ent_Docs#page1.tif	
source=26413US01_Original_Assignment_Docs#page2.tif		
source=26413US01_Original_Assignment_Docs#page3.tif		
source=26413US01_Original_Assignment_Docs#page4.tif		
source=26413US01_Original_Assignment_Docs#page5.tif		
source=26413US01_Original_Assignment_Docs#page6.tif		
source=26413US01_Original_Assignment_Docs#page7.tif		
source=26413US01_Original_Assignment_Docs#page8.tif		
source=26413US01_Original_Assignment_Docs#page9.tif		
source=26413US01_Original_Assignment_Docs#page10.tif		

source=26413US01_Original_Assignment_Docs#page11.tif source=26413US01_Original_Assignment_Docs#page12.tif



United States Patent and Trademark Office

Home | Site Index | Search | Guides | Contacts | eBusiness | eBiz alerts | News |



Electronic Patent Assignment System

Confirmation Receipt

Your assignment has been received by the USPTO. The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Ugur Sahin	01/17/2013
Ozlem Tureci	01/21/2013
Michael Koslowski	01/19/2013
Korden Walter	01/17/2013
Maria Kreuzberg	01/17/2013
Sylvia Luxen	. 01/17/2013

RECEIVING PARTY DATA

Name:	Ganymed Pharmaceuticals AG
Street Address:	Freiligrathstrasse 12
City:	Mainz
State/Country:	GERMANY
Postal Code:	55131

Johannes Gutenberg-Universitat Mainz
Saarstrasse 21
Mainz
GERMANY
55122

PROPERTY NUMBERS Total: 1

Property Type	Number		
	13808423		
CORRESPONDENCE DATA			
Fax Number: 3127758100 Phone: 312-775-8000 Email: rkieltyka@mcandrews-ip.com Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail. Correspondent Name: McAndrews, Held & Malloy Ltd. Address Line 1: 500 W. Madison Street Address Line 2: Suite 3400 Address Line 4: Chicago, ILLINOIS 60661			
ATTORNEY DOCKET NUMBER:	26413US01		
NAME OF SUBMITTER:	Timothy M. Long		
Signature:	/Timothy M. Long/		
Date:	03/18/2013		
Total Attachments: 8 source=26413US01_Assignment#page1.tif source=26413US01_Assignment#page2.tif source=26413US01_Assignment#page3.tif source=26413US01_Assignment#page4.tif source=26413US01_Assignment#page5.tif source=26413US01_Assignment#page6.tif source=26413US01_Assignment#page7.tif source=26413US01_Assignment#page8.tif			
RECEIPT INFORMATION			
EPAS ID: PAT231 Receipt Date: 03/18/20 Fee Amount: \$40	- 1		

Return to home page

| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Maria Kreuzberg, and Sylvia Luxen (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO" and identified as Case No. 26413US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on January 4, 2013, in the United States Patent and Trademark Office as Serial No. 13/808,423 (the "'423 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '423 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '423 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this <u>17</u> day of <u>0</u> , 2013.	Onch
WITNESSED by (Ha Nagel	this _ / 7 day of _ 0 (_, 2013.
EXECUTED this 21 day of 01, 2013.	Jellie e
WITNESSED by Aynur Cavas Kral	Özlem Türeci $\frac{1}{2}$ this $\frac{21}{2}$ day of $\frac{01}{2}$, 2013.
EXECUTED this day of, 2013.	
	Michael Koslowski
WITNESSED by	_ this day of, 2013.
EXECUTED this 17 day of 01, 2013.	
	Korden Walter
WITNESSED by Aynus Cavas-Kira	this $\sqrt{7}$ day of $\sqrt{0}$, 2013.

EXECUTED this 17 day of 01, 2013.
Maria Kreuzberg
Maria Kreuźberg
WITNESSED by Aynur Cavas Kiralli this 17 day of 01, 2013.
EXECUTED this
Sylvia Luxen
WITNESSED by Aynur Caus Krazl this 17 day of 01, 2013.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Maria Kreuzberg, and Sylvia Luxen (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO" and identified as Case No. 26413US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on January 4, 2013, in the United States Patent and Trademark Office as Serial No. 13/808,423 (the "'423 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '423 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '423 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

REEL: 039641 FRAME: 0351

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this day of, 2013.		
		Ugur Sahin
WITNESSED by	this	day of, 2013.
EXECUTED this day of, 2013.		
	No. of the second secon	Özlem Türeci
WITNESSED by	this	day of, 2013.
EXECUTED this Ag day of Applicated 2013.	X	Mals
WITNESSED by On bone	(this	Michael Koslowski A day of Man 2013.
EXECUTED this day of, 2013.		V
		Korden Walter
WITNESSED by	this	day of, 2013.

Case No. 26413US01

EXECUTED this day of, 2013.			
	Maria Kreuzberg		
WITNESSED by	this	day of	, 2013.
EXECUTED this day of, 2013.			
	Sylvia Luxen		
WITNESSED by	this	day of	2013

PATENT REEL: 039641 FRAME: 0354

RECORDED: 08/10/2016